Universal Cancer Vaccine Launches Phase 2 Clinical Trial

In COVID-19, Latest News by Precision Vaccinations

A Phase II randomized clinical trial will evaluate a proprietary universal cancer vaccine, UV1, in patients with recurrent or metastatic head and neck cancer who will be treated with standard of care therapy pembrolizumab.
UV1 is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.
The trial will be conducted at ten sites across Germany and led by principal investigator Prof. Mascha Binder, M.D., Medical Director, and Head of the Immunological Tumor Group at University Medicine Halle, Germany.

Read More